Ofatumumab + Chlorambucil vs Chlorambucil Monotherapy in Previously Untreated Patients With Chronic Lymphocytic Leukemia

NCT00748189 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

447

Enrollment

INDUSTRY

Sponsor class

Stopped Majority of patients (62%) had been treated with next line therapies, including new highly effective therapies confounding the interpretation of the OS results.

Conditions

Leukaemia, Lymphocytic, Chronic

Interventions

DRUG: chlorambucil, tablets
DRUG: ofatumumab (GSK1841157) infusion

Sponsor

Novartis Pharmaceuticals